Last reviewed · How we verify
NCT03678584
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
NA trial testing Medium Supplemented with Chaetoglobosin A in Infertility in 300 participants. Completed in 3 May 2019.
2 May 2019
Quick facts
| Lead sponsor | Ibn Sina Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 300 |
| Start date | 25 September 2018 |
| Primary completion | 2 May 2019 |
| Estimated completion | 3 May 2019 |
| Sites | 3 locations across Egypt |
Drugs / interventions tested
- Medium Supplemented with Chaetoglobosin A
Conditions studied
- Infertility — all drugs for Infertility →
Sponsor
Ibn Sina Hospital
Who can join
Adults 18 to 42, female only, with Infertility. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Chaetoglobosin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Chaetoglobosin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03678584
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Infertility
Currently open trials in the same condition.
- NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
- NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
- NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
- NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
- NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting
Other Ibn Sina Hospital trials
Trials by the same sponsor.
- NCT02896777 — Triple-arm pH Comparison · NA · completed
- NCT06503835 — Efficacy of Transforaminal Epidural Steroid and Its Combination With Ozone in Lumbar Radiculopathy · completed
- NCT04210414 — Cleave-stage Transfer on Day 3 Versus Day 5 Transfer When Only One Embryo Available · NA · terminated
- NCT04052607 — Progestin Priming Ovarian Stimulation (PPOS) Compared With Antagonist Protocol for Freeze-all Cycles · NA · terminated
- NCT03823235 — Humidified Culture and Live Birth After ICSI · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03678584 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ibn Sina Hospital
- Last refreshed: 7 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03678584.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing